Physician profile
Joti Patel
NPI 1295496032
$1,402.77
in general payments reported to CMS, 2019-2025
20 companies · $50.65 in 2025
The $50.65 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $616 · 2023: $664 · 2024: $71.75 · 2025: $50.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $251.70 | 2022-2023 | Ultomiris, Soliris |
| Abbvie INC. | $181.17 | 2022-2025 | |
| Medtronic, INC. | $158.75 | 2022 | |
| Neurelis, INC. | $155.50 | 2022-2023 | Valtoco |
| Celgene Corporation | $117.16 | 2023 | Zeposia |
| Alnylam Pharmaceuticals INC. | $113.57 | 2022-2023 | Amvuttra |
| Lundbeck LLC | $89.03 | 2022-2023 | Vyepti |
| Ucb, INC. | $63.32 | 2022-2023 | Briviact |
| Lilly USA, LLC | $34.09 | 2023-2024 | Kisunla, Amyvid |
| Argenx US, INC. | $33.97 | 2022 | |
| Viz.Ai, INC. | $31.29 | 2022 | |
| Acorda Therapeutics, INC | $29.56 | 2023 | Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $27.00 | 2023 | Gammagard |
| Kyowa Kirin, INC. | $21.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.76 | 2024 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17.05 | 2022 | |
| Merz Pharmaceuticals, LLC | $17.05 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $16.20 | 2022 | |
| Impel Pharmaceuticals INC. | $14.29 | 2023 | Trudhesa |
| Curonix LLC | $13.24 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joti Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.